Clinical Trial Update: A Study of CSTI-500 in Patients With Prader-Willi Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of CSTI-500 for Prader-Willi syndrome is announced, though it is not yet recruiting. The sponsor listed is ConSynance Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• CSTI-500

Snippet

Sponsor: ConSynance Therapeutics | Conditions: Prader-Willi Syndrome | Phase 2 | Status: NOT_YET_RECRUITING